Global Invasive Bacterial Vaccine-Preventable Diseases Surveillance-2008-2014

• Authors: Jillian Murray, World Health Organization (WHO); Mary Agocs, World Health Organization (WHO); Fatima Serhan, World Health Organization (WHO); Simarjit Singh, World Health Organization (WHO); Maria Deloria-Knoll, Johns Hopkins University; Katherine O'Brien, Johns Hopkins University; Jason M. Mwenda, WHO Regional Office for Africa; Richard Mihigo, WHO Regional Office for Africa; Lucia Oliveira, WHO Regional Office for the Americas; Nadia Teleb, WHO Regional Office for the Eastern Mediterranean; Hinda Ahmed, WHO Regional Office for the Eastern Mediterranean; Annemarie Wasley, WHO Regional Office for Europe; Doville Videbaek, WHO Regional Office for Europe; Pushpa Wijesinghe, WHO Regional Office for South-East Asia; Arun Bhadra Thapa, WHO Regional Office for South-East Asia; Kimberly Fox, WHO Regional Office for the Western Pacific; Fem Julia Paladin, WHO Regional Office for the Western Pacific; Rana Hajjeh, Centers for Disease Control and Prevention; Stephanie Schwartz, Centers for Disease Control and Prevention; Chris Van Beneden, Centers for Disease Control and Prevention; Terri Hyde, Centers for Disease Control and Prevention; Claire Broome, Emory University; Thomas Cherian, World Health Organization (WHO)
• Journal Title: MMWR. Morbidity and mortality weekly report
• Volume: Volume 63, Number 49
• Publisher: Centers for Disease Control and Prevention | 2014-12-12, Pages 1159-1162
• Type of Work: Article | Final Publisher PDF
• Subjects: Health Sciences, Immunology
• Keywords: Science & Technology; Life Sciences & Biomedicine; Public, Environmental & Occupational Health

Abstract

Meningitis and pneumonia are leading causes of morbidity and mortality in children globally infected with Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis, and Haemophilus influenzae causing a large proportion of disease. Vaccines are available to prevent many of the common types of these infections. S. pneumoniae was estimated to have caused 11% of deaths in children aged <5 years globally in the pre-pneumococcal conjugate vaccine (PCV) era. Since 2007, the World Health Organization (WHO) has recommended inclusion of PCV in childhood immunization programs worldwide, especially in countries with high child mortality. As of November 26, 2014, a total of 112 (58%) of all 194 WHO member states and 44 (58%) of the 76 member states ever eligible for support from Gavi, the Vaccine Alliance (Gavi), have introduced PCV. Invasive pneumococcal disease (IPD) surveillance that includes data on serotypes, along with meningitis and pneumonia syndromic surveillance, provides important data to guide decisions to introduce PCV and monitor its impact.